pre

Search documents
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
Globenewswire· 2025-07-01 11:00
Core Insights - Avacta Group plc has appointed David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as an advisor in business development, aiming to enhance its clinical strategy and business development efforts [1][5] Company Overview - Avacta is a clinical-stage life sciences company focused on developing targeted oncology drugs, utilizing its proprietary pre|CISION platform to deliver potent cancer therapies while minimizing damage to normal tissues [7] Leadership Background - Dr. Liebowitz brings over 30 years of experience in hematology-oncology and drug development, having successfully filed more than 25 Investigational New Drug (IND) applications [2] - Prior to joining Avacta, Dr. Liebowitz held senior positions at Inovio Pharmaceuticals, Xencor, Vaxart, and Amgen, focusing on oncology and immunotherapy [2] - Mr. Bogatyrenko has extensive experience in business development and commercial strategy, having led global drug launches and partnerships at major pharmaceutical companies like Pfizer, Bayer, and Teva [4] Strategic Importance - The appointments of Dr. Liebowitz and Mr. Bogatyrenko are seen as pivotal for Avacta, as they aim to advance the company's clinical development strategy and corporate growth [5]
Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
Globenewswire· 2025-05-28 11:00
LONDON and PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti- tumor payloads directly to the tumor, today announces the appointments of David Bryant and Richard Hughes as Non-Executive Directors with immediate effect. David Bryant is a highly experienced international pharmaceutical executive with over 35 years in the industry. He has a strong track record in commercial lead ...
Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting
Globenewswire· 2025-04-28 11:01
Core Insights - Avacta Therapeutics announced promising Phase 1 data for its lead program FAP-Dox (AVA6000), showing preliminary efficacy in salivary gland cancers and a favorable safety profile with no severe cardiac toxicity [1][3][4] - The Phase 1a study demonstrated a disease control rate of 91% in patients with salivary gland cancers, with median progression-free survival (PFS) not yet reached, indicating a significant improvement over previous benchmarks [5][6] - The proprietary pre|CISION platform targets fibroblast activation protein-alpha (FAPα), allowing for tumor-localized drug activation, which enhances efficacy while minimizing systemic toxicity [2][11] Clinical Data Highlights - AVA6000 was well-tolerated in a Phase 1a dose-escalation study, with no maximum tolerated dose reached despite dosing up to 385 mg/m² every three weeks [4][6] - In a cohort of 11 patients with salivary gland cancers treated at or above 250 mg/m², multiple confirmed responses were observed, and the median follow-up exceeded 25 weeks [5][7] - The exposure of released doxorubicin in plasma and normal tissues was lower than that of conventional doxorubicin, with a median tumor to plasma ratio of 100:1, further supporting its improved safety profile [6][11] Future Developments - Full Phase 1a data across all patients, including cardiac safety assessments, are expected in the second half of 2025 [7] - Avacta is enrolling patients in three Phase 1b expansion cohorts targeting salivary gland cancer, triple negative breast cancer, and high-grade soft tissue sarcoma, with data anticipated by the end of 2025 [7]
Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting
Globenewswire· 2025-04-28 11:00
FAP-EXd (AVA6103) demonstrates tumor growth inhibition and durable complete responses in multiple therapy-resistant preclinical models AVA6103 (FAP-EXd) Preclinical Candidate Highlights (Abstract 3139, 28 April 2025) Avacta presented preclinical data from its second clinical candidate, AVA6103, a novel FAP-activated pre|CISION PDC delivering the topoisomerase I inhibitor exatecan directly to the tumor-stroma interface. This mechanism minimizes systemic toxicity while ensuring precise delivery of the cytotox ...